Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Foundation Medicine's FoundationOne; Omixon's Target

Premium

Foundation Medicine has launched FoundationOne, its targeted sequencing-based cancer test, which screens for mutations in 200 cancer-related genes. The test is offered out of the company's CLIA certified laboratory on the Illumina HiSeq 2000 with a turnaround time of 21 days. The test must be ordered by a physician and is used to match genomic alterations with a targeted therapy or clinical trial.


Omixon has launched Target, software analysis for targeted sequencing data designed for diagnostic labs looking to adopt next-gen sequencing. According to the company, Target uses profiles with parameters set up for the particular gene target, to ensure precision for diverse assays, such as oncogenes or immune-system genes.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.